Expiration date: 07/2025
Composition
1 tablet contains drotaverine hydrochloride 40 mg
Packaging
28 PCs
Pharmacological action:
Drotaverine is an antispasmodic myotropic actions. The chemical structure and pharmacological properties close to papaverine, but it is superior in efficiency and duration of action. Drotaverine reduces the tone of smooth muscles of internal organs, reduces their motor activity. It has a vasodilating effect.
Indications:
Prevention and treatment functional disorders and pain syndrome caused by spasm of smooth muscles (including spasms of the gastrointestinal tract, urinary tract, associated with cholelithiasis, cholecystitis, gastric ulcer, duodenal ulcer, spasm of the pyloric and cardia of the stomach, spastic constipation, spastic colitis, proctitis, tenesmus, post-operative colic due delay gas in connection with nephrolithiasis, pyelitis), with conduct of the research tools, spasms of peripheral arteries, brain vessels, algomenorrhea.
To reduce the excitability of the uterus during pregnancy, uterine pharyngeal spasm in childbirth, prolonged opening of the pharynx, postpartum contractions, threatening abortion.
Contraindications:
Hypersensitivity to the components of the drug, expressed hepatic and renal failure, severe heart failure (low cardiac output syndrome), lactation.
This drug form is not used in children under 3 years.
Due to the presence of the drug lactose monohydrate (milk sugar), its reception is contraindicated in congenital lactose intolerance, lactase deficiency, glucose-galactose malabsorption.
Dosage and administration
Drotaverine is taken orally. Adults-40-80 mg (1-2 table.) 2-3 times a day. Children: up to 6 years-in a single dose of 10-20 mg (1/4-1/2 table.), 6-12 years-20 mg (1/2 table.) 1-2 times a day.
Side effect:
Dizziness, headache, insomnia, palpitations, low blood pressure, allergic reactions, nausea, constipation, feeling of heat, sweating.
Special instruction
In the treatment of gastric ulcer and duodenal ulcer is used in combination with other drugs, usually prescribed for the treatment of this group of diseases of the esophagus, stomach and duodenum.
When taken orally in therapeutic doses, drotaverine has no effect on the ability to drive and perform work requiring increased attention. If there are any side effects, the question of driving and working on the machines requires individual consideration.
Drug interaction
While the use of can weaken the antiparkinsonian effect of levodopa.
Enhances the effect of papaverine, bendazole and other antispasmodics (including
m-cholinoblockers), lowering blood pressure caused by tricyclic antidepressants, quinidine and procainamide.
Spazmogennoe reduces the activity of morphine.
Phenobarbital increases the severity have spasmolytic action drotaverina.
Storage conditions
In a dry place, protected from light and out of reach of children, at a temperature not exceeding 25°C.
Shelf life
3 years.
